PensionDanmark Pensionsforsikringsaktieselskab Increases Position in Gilead Sciences, Inc. $GILD

PensionDanmark Pensionsforsikringsaktieselskab increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.3% during the 2nd quarter, Holdings Channel reports. The firm owned 233,799 shares of the biopharmaceutical company’s stock after acquiring an additional 25,515 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in Gilead Sciences were worth $29,538,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Aviva PLC grew its holdings in Gilead Sciences by 5.4% during the 4th quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock valued at $141,978,000 after buying an additional 59,782 shares in the last quarter. Life Cycle Investment Partners Ltd bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $1,418,000. NBC Securities Inc. lifted its holdings in shares of Gilead Sciences by 150.3% in the fourth quarter. NBC Securities Inc. now owns 17,147 shares of the biopharmaceutical company’s stock worth $2,105,000 after buying an additional 10,296 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Gilead Sciences by 43.9% in the fourth quarter. Farther Finance Advisors LLC now owns 56,812 shares of the biopharmaceutical company’s stock worth $6,973,000 after buying an additional 17,325 shares in the last quarter. Finally, Flputnam Investment Management Co. boosted its position in shares of Gilead Sciences by 66.5% during the fourth quarter. Flputnam Investment Management Co. now owns 105,740 shares of the biopharmaceutical company’s stock worth $12,978,000 after acquiring an additional 42,243 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on GILD shares. The Goldman Sachs Group raised their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. Morgan Stanley decreased their price target on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research note on Monday, July 27th. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 price objective on shares of Gilead Sciences in a report on Wednesday. Citigroup raised their price objective on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Finally, Truist Financial reduced their target price on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Twenty-five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $158.04.

Insiders Place Their Bets

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00. Following the sale, the chief executive officer owned 592,133 shares of the company’s stock, valued at approximately $77,160,851.23. This represents a 2.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the transaction, the chief financial officer directly owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. This represents a 1.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 82,000 shares of company stock valued at $10,641,790 over the last three months. 0.30% of the stock is owned by company insiders.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported second-quarter revenue of $7.8 billion, above the roughly $7.4 billion consensus estimate. Product sales excluding Veklury rose 10% year over year to $7.6 billion, led by HIV medicines and Trodelvy. GILD Q2 Earnings Beat
• Positive Sentiment: Management raised its HIV growth outlook to 9%–10% and highlighted rapid adoption of Yeztugo, its HIV prevention treatment. PrEP sales reportedly doubled to approximately $1 billion, supporting the view that HIV remains Gilead’s primary growth engine. Q2 Earnings Call Highlights
• Positive Sentiment: Several analysts remain constructive: Cantor Fitzgerald reiterated an Overweight rating with a $155 target, while Needham reaffirmed Buy with a $170 target. Gilead also declared its $0.82 quarterly dividend, providing continued income support.
• Neutral Sentiment: The quarter was described as operationally strong, but reported earnings guidance remains negative because of acquisition-related charges and elevated research spending. The company’s 2026 base-business sales outlook is approximately $29.8 billion–$30.1 billion.
• Negative Sentiment: Gilead posted a $6.75 per-share quarterly loss versus $2.01 of earnings a year earlier. The loss was driven largely by acquisition-related costs, increasing concern about near-term profitability despite the revenue beat. Strong Quarter Hidden Behind Ugly Earnings
• Negative Sentiment: MSD and Gilead discontinued a Phase III Trodelvy-Keytruda study after lacklustre interim data. The failure weakens expectations for expanding Trodelvy’s use in combination therapy and adds uncertainty to Gilead’s oncology growth strategy. Trodelvy-Keytruda Study Discontinued
• Negative Sentiment: Veklury sales continued to decline sharply, while AIDS Healthcare Foundation criticized Gilead’s HIV pricing and access policies. The controversy could create reputational or longer-term market-access risks. CEO Daniel O’Day’s planned sale of 15,000 shares was a minor additional negative signal.

Gilead Sciences Trading Down 0.7%

Shares of GILD opened at $130.86 on Friday. The stock has a market capitalization of $162.47 billion, a PE ratio of -49.01 and a beta of 0.32. The company’s fifty day moving average is $129.43 and its 200 day moving average is $136.22. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.14. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business’s revenue was up 10.6% on a year-over-year basis. During the same period last year, the company posted $2.01 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post -0.65 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.